Investigational drug · Phase 2
REGN13335
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pulmonary Arterial Hypertension (PAH).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "REGN13335"
First trial start
2026
May 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN13335", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Arterial Hypertension (PAH)
Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN13335" as an intervention, largest first.
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07318597 · 99 participants (planned) · Start May 6, 2026 · Primary completion Feb 27, 2028
Drug: REGN13335; Placebo · For: Pulmonary Arterial Hypertension (PAH)
Sites: Aurora, Colorado; Boston, Massachusetts; Omaha, Nebraska · 33 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06137482 · 56 participants · Start Dec 6, 2023 · Primary completion Feb 11, 2025
Drug: REGN13335; Matching Placebo · For: Healthy Volunteers
Sites: Christchurch, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Pulmonary Arterial Hypertension (PAH)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.